rates

NYSE Content Advisory: Pre-Market update + Traders See 55% Chance Fed Holds Rates Steady

NEW YORK, Nov. 17, 2025 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from…

3 weeks ago

NYSE Content Advisory: Pre-Market update + Futures Show 50% Odds of Fed Maintaining Rates

NEW YORK, Nov. 14, 2025 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from…

3 weeks ago

Elixir Medical Announces Significant Late Breaking Clinical Results for DynamX Bioadaptor Demonstrating Nearly 50% Reduction in Coronary Event Rates vs. Current PCI Standard of Care

Results were presented at the Transcatheter Cardiovascular Therapeutics (TCT) Conference 2025 in San Francisco on October 27, 2025 DynamX® bioadaptor…

1 month ago

ITM Announces Analyses from Phase 3 COMPETE Data Showing Higher Objective Response Rates with n.c.a. 177Lu-edotreotide (ITM-11) vs. Everolimus Across Subgroups of Patients with GEP-NETs at NANETS 2025 Annual Symposium

Austin, Texas, October 25, 2025 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, announced analyses data…

1 month ago

NYSE Content Advisory: Pre-Market Update + Fed cuts interest rates by 0.25%

NEW YORK, Sept. 18, 2025 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from…

3 months ago

ESHRE 41st Annual Meeting: Older paternal age linked to higher miscarriage risk and lower live birth rates in donor egg IVF cycles

A new international study presented today at the 41st Annual Meeting of the European Society of Human Reproduction and Embryology…

5 months ago

CoinDesk Overnight Rates (CDOR) to Support Stablecoin Money Markets based on Aave

These first-of-kind money market rates transform Aave pool activity into conventional overnight rates to support interest rate derivatives and floating…

6 months ago

Genmab Announces Epcoritamab Investigational Combination Therapy Demonstrates High Response Rates in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Eligible for Autologous Stem Cell Transplantation (ASCT)

Media ReleaseCOPENHAGEN, Denmark; June 15, 2025 Results from the EPCORE® NHL-2 trial show investigational treatment with epcoritamab in combination with…

6 months ago

Manufacturers and Logistics Providers Embrace AI for Enhanced Barcode Reading Performance

Survey reveals 90% of users anticipate AI will improve accuracy, ease of use, decode rates, and more NATICK, Mass., June…

6 months ago